Comparison of Candesartan vs Amlodipine Comparison of ...

More documents

Recommendations

Info

Candesartan vs vs Standard Standard with ACEi Primary endpoint MACE CV death + MI UAP HF Stroke other CV events Secondary endpoints Candesartan ACEi HR P (n=1024) (n=723) [95%CI] value 264 (25.8%) 57 (5.6%) 151 (14.7%) ( %) 40 (3.9%) 45 (4.4%) 35 (3.4%) 203 (28.1%) 40 (5.5%) 117 (16.2%) 35 (4.8%) 38 (5.3%) 27 (3.7%) 0.90 [0.75-1.08] 1.01 [0.67-1.51] 0.90 [0.70-1.14] [ ] 0.80 [0.51-1.26] 0.83 [0.54-1.27] 0.91 [0.55-1.50] 0.24 0.96 0.38 0.34 0.39 0.70 revascularization 256 (25.0%) 192 (26.6%) 0.92 [0.77-1.12] 0.41 NNew-onset tDM DM 7/645 (1.1%) (1 1%) 12/418 (2.9%) 037[0150 0.37 [0.15-0.94] 94] 0.04
Secondary Secondary Endpoint 30% 20 10 0 30% 20 10 0 Drug-related AE P=0.027 CAN STN Hyperkalemia P=0.410 CAN STN 30% 20 10 0 30% 20 10 0 Cough P
Page 1 and 2:
Comparison of Candesartan vs Amlodi
Page 3 and 4:
30 20 10 0 ‐10 ‐20 ‐30 ‐40
Page 5 and 6:
LIFE Incidence of Diabetes Mellitus
Page 7 and 8: m2 Change in LVVMI (g/m ) LIFE Echo
Page 9 and 10: ARBs for New-onset Atrial Fibrillat
Page 11 and 12: % New-onset AF with ARB Preventive
Page 14 and 15: Beyond BP effect of ARBs • Hi Hig
Page 16 and 17: CASE CASE-J CASE J CCandesartan d t
Page 18 and 19: Outline of the study Objectives : A
Page 20 and 21: Dosage Schedule Schedule 1 month BP
Page 22 and 23: Endpoints Primary imary Endpoints A
Page 24 and 25: Patient Characteristics Ttl Total n
Page 26 and 27: Antihypertensive Antihypertensive D
Page 28 and 29: Comparison of Cardiovascular Cardio
Page 30 and 31: Time Time-specific Time Time-specif
Page 32 and 33: Renal Renal Events Events per 1000
Page 34 and 35: CASE-J vs. VALUE
Page 36 and 37: Primary endpoint VALUE (Valsartan)
Page 38 and 39: BP reduction during studies mmHg SB
Page 40 and 41: All-cause mortality (CASE-J Primary
Page 42 and 43: New New-onset New New-onset onset D
Page 44 and 45: Conclusions Candesartan and Amlodip
Page 46 and 47: Background ACE ACE-inhibitors i hib
Page 48 and 49: Eligibility Inclusion criteria : An
Page 50 and 51: Endpoint Primary Endpoint Major Adv
Page 52 and 53: Patient Characteristics (1) Candesa
Page 54 and 55: Medications at at Randomization Ran
Page 56 and 57: Primary Primary Endpoint Cumulative
Page 60 and 61: Subgroup Subgroup analysis analysis
Page 62 and 63: Summary IIn comparison i with i h s
Page 64: Conclusions Candesartan and Amlodip
Page 68 and 69: % Isolated systolic hypertension 0
Page 70: Predictors of new-onset atrial fibr
show all

Comparison of Candesartan vs Amlodipine Comparison of ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?